Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus - PubMed

Review

Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus

Y J Bryson. J Antimicrob Chemother. 1983 Sep.

Abstract

Herpes simplex genitalis is an increasingly common primary or recurrent HSV infection. Acyclovir (ACV) has been found to diminish virus shedding and clinical symptoms in patients with first episode genital HSV when given topically or intravenously. As most patients with first episode disease do not require hospitalization and recurrent disease is usually less severe than the primary infection, out-patient treatment forms the basis of practical management. Acyclovir is absorbed orally with plasma concentrations which exceed in vitro inhibitory concentrations for HSV1 and HSV2. In double blind studies in over 100 recipients with first episode HSV, oral ACV treatment (200 mg, 5 times daily) significantly reduced virus shedding, new lesion formation, duration of genital lesions and clinical symptoms in both men and women when compared with placebo recipients. No toxicity was observed. Recurrence rates following the first episode were similar in placebo and ACV groups. A multi-centre double blind trial of oral ACV treatment of recurrent HSV infection in 250 patients showed that the duration of virus shedding and lesions was significantly shorter in ACV versus placebo recipients. These effects were more pronounced when therapy was self-initiated by patients early on during a recurrence or during the prodromal period. Oral acyclovir has significant clinical and virological effects in both primary and recurrent genital HSV infections.

Similar articles

• Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.

  Reichman RC, Badger GJ, Mertz GJ, Corey L, Richman DD, Connor JD, Redfield D, Savoia MC, Oxman MN, Bryson Y, et al. Reichman RC, et al. JAMA. 1984 Apr 27;251(16):2103-7. JAMA. 1984. PMID: 6368877 Clinical Trial.

• Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection.

  Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, Connor J, Redfield DC, Savoia MC, Richman DD, Tyrrell DL, et al. Mertz GJ, et al. JAMA. 1984 Sep 7;252(9):1147-51. JAMA. 1984. PMID: 6088819 Clinical Trial.

• Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects.

  Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, Johnson BL, Wiesmeier E, Growdon W, Creagh-Kirk T, Keeney R. Bryson YJ, et al. N Engl J Med. 1983 Apr 21;308(16):916-21. doi: 10.1056/NEJM198304213081602. N Engl J Med. 1983. PMID: 6339923 Clinical Trial.

• Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.

  Corey L, Benedetti J, Critchlow C, Mertz G, Douglas J, Fife K, Fahnlander A, Remington ML, Winter C, Dragavon J. Corey L, et al. J Antimicrob Chemother. 1983 Sep;12 Suppl B:79-88. doi: 10.1093/jac/12.suppl_b.79. J Antimicrob Chemother. 1983. PMID: 6355054 Review.

• Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy.

  Fiddian AP, Kinghorn GR, Goldmeier D, Rees E, Rodin P, Thin RN, de Konig GA. Fiddian AP, et al. J Antimicrob Chemother. 1983 Sep;12 Suppl B:67-77. doi: 10.1093/jac/12.suppl_b.67. J Antimicrob Chemother. 1983. PMID: 6355053 Review.

Cited by

• Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

  Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A. Agyemang E, et al. J Infect Dis. 2018 Oct 20;218(11):1691-1699. doi: 10.1093/infdis/jiy372. J Infect Dis. 2018. PMID: 30020484 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program